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Abstract. The distribution of COVID-19 vaccines has proved to be a
challenging task for public health authorities in many countries. Among
several decisions involved in the task, allocating limited available vaccines
to administration points is indeed critical. However, the operation man-
agement literature lacks evidence-based mathematical models that could
support effective, efficient, sustainable and equitable vaccine allocation
decision. This paper develops the fundamentals of a decision support sys-
tem for COVID-19 vaccine allocation inside countries. The proposed DSS
intends to support public health authorities in real-time by illustrating
possible vaccine alternatives. The system could also inform and support
other actors in the COVID19 distribution for planning and collabora-
tion. Two illustrative cases for the COVID-19 vaccine allocation have
been investigated to highlight potential benefits of our methodology.
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1 Introduction
Several reports indicate that COVID-19 vaccines distribution has proved to be
a challenging task for public health authorities in many countries (e.g., Logmore
[19]). When COVID-19 vaccines arrive at a country’s main entry point, public
health authorities have to make critical logistics decisions to deliver vaccines to
administration points. Such decisions could be long-term (e.g., where to locate
storage facilities) as well as mid- and short-term (e.g., how many vaccines to be
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allocated to facilities, and how to transport vaccines to corresponding locations)
[20].
Recent surveys indicate that effectiveness, efficiency, sustainability, and eq-
uity are important objectives for critical logistics decisions in vaccine distribution
[11]. Here, by effectiveness, research refers to maximising the impact of vacci-
nation by ensuring that delivered vaccines meet the vaccination demands. The
efficiency objective concerns with reducing total logistics costs such as storage
and transportation costs. The sustainability objective relates to reducing the
footprint of the logistics. Finally, the equity objective reflects ensures that the
focus is on prioritised and vulnerable groups while meeting overall demands.
Majority of operations management research on vaccine distribution focuses
on proposing mathematical models to support public health authorities [12].
However, three research gaps could be observed. First, research to support al-
locating vaccines in the presence of different priority groups, multiple vaccines
with distinct features, and variety capacity constraints is scant. The literature
has mainly focused on developing mathematical models to support strategic
decisions in vaccine distribution such as locating vaccine storage facilities or lo-
cating mobile vaccine administration units (cf. Section 2). Second, To the best
of our knowledge, there is no study that seeks to simultaneously balance the four
abovementioned objectives for vaccine allocation. Recent surveys (e.g., De Boeck
et al. [11]) show that few studies have considered the equity objective in their
models although it is a critical objective in the vaccine allocation [2]. Third,
few studies propose evidence-based mathematical models (i.e., models that have
been informed by insights or evidence from practice or have been validated by
data from real cases [5]). In the absence of evidence-based models, public health
authorities are often reluctant to use research findings for vaccine allocation in
practice.
Our research aims to address the three abovementioned gaps. It seeks to
answer: how can we support public health authorities for COVID-19 vaccine al-
location? Our ultimate objective is to develop an intuitive web-based decision
support system (DSS). A typical DSS for logistics problems with multiple ob-
jectives and different decision-makers (DMs) can consist of four components
as illustrated in Figure 1. Our study contributes to the first DSS component
by developing an evidence-based mathematical model (through a mixed-method
approach). Our model balances effectiveness, efficiency, sustainability and equity
objectives for COVID-19 vaccine allocation.
Fig. 1. Proposed DSS adapted from Baharmand et al. [5]
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We acknowledge that such a DSS should consider the perspectives of stake-
holders for the vaccine distribution network such as health ministries, logistics
service providers, hospitals, pharmacies, and others [13]. That said, in this paper,
we intend to (i) position our contribution within the existing literature (ii) de-
scribe the methodology for developing the system (iii) share an initial illustrative
example, and (iv) draft a roadmap for future research on this subject.
The rest of the paper is organised as follows. Section 2 describes the back-
ground on DSS for vaccines distribution. Section 3 presents the proposed method-
ology. Section 4 includes primary results and discussion. Section 5 concludes the
paper and outlines future work.
2 Background
2.1 In-country vaccine distribution network
The design of an in-country vaccine distribution network is a complex socio-
technical problem (i.e, it includes both human and technical factors) [1, 8]. In
the design of vaccine distribution network, strategic and tactical decisions are
of high importance [10]. These decisions could be investigated from a global
(from manufacturer to the countries), in-country (from main entry points to
administration centres), or integrated perspective (comprising both global and
in-country). Figure 2 shows an example of COVID-19 in-country vaccine distri-
bution network. For this network, the tactical decisions category comprises the
allocation decision: the amount of vaccines to be shipped from main entry points
to health facilities in a hierarchical way .
Fig. 2. Illustration of in-country vaccine distribution without local manufacturers
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Compared to strategic counterparts, the tactical decisions are of high impor-
tance in the in-country vaccine distribution network in pandemics. This is due
to the allocation challenge given the urgency of delivering vaccines to several
health facilities and vulnerable groups, uncertainties in costs, perishability of
vaccines, wastage in storage, limited capacity in facilities, and demand priorities
in remote areas [24].
Moreover, infrastructure disruptions, the propagation of disease, efficacy of
vaccines, and immunity duration result in huge uncertainty in both demands and
supply. Furthermore, factors such as the production time of vaccines can add to
the complexity of designing in-country vaccine supply chains. Furthermore, the
design of in-country vaccine supply chains has multiple stakeholders such as
pharmacies, hospitals, international organisations, government, manufacturers,
people to be vaccinated, and many more who may have different preferences and
constraints during the pandemic response [13].
2.2 Decision support for vaccine distribution
To support pandemic responders, operations management researchers have pro-
posed different mathematical models for designing vaccine distribution networks.
De Boeck et al. [10]’s recent survey shows that literature has mainly concentrated
on the strategic and operational decision levels while research on decisions at the
tactical level (i.e., allocation in the in-country network) is scant. That said, in
this section, we consider models that address the general vaccine distribution
problem.
Formulated objectives comprise an important feature of mathematical mod-
els for supporting vaccine distribution. Lemmens et al. [18] conduct a systematic
literature review on the design of vaccine supply chains and contend that while
the efficiency and effectiveness criteria are important, the design of such supply
chains should account for sustainability, too. Moreover, a recent study confirms
that including the equity objective, in vaccine distribution models is of stake-
holders’ interest [21]. Abila et al. [2] explore the previous successful public health
strategies to test whether they could influence the uptake of COVID-19 vaccines
and stress the need for equitable access to vaccines worldwide.
However, research on equitable vaccine distribution is rather new and scarce
in the literature. Enayati and Özaltın [14] propose a mathematical model for
equitable influenza vaccine distribution. They divided the population into sev-
eral subgroups and prevented the epidemic outbreaks by equitably allocating
the necessary vaccines to each subgroup. Rastegar et al. [23] develop a math-
ematical model for equitable influenza vaccine distribution by considering the
possibility of storage for future periods, being faced with a shortage, and budget
constraints. More recently, Tavana et al. [25] present a mathematical model for
equitable COVID-19 vaccine distribution in developing countries. In their study,
vaccines are grouped into cold, very cold, and ultra-cold categories where spe-
cific refrigeration is required for their storage and distribution. The possibility
of storage for future periods, facing a shortage, budgetary considerations, man-
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ufacturer selection, order allocation, time-dependent capacities, and grouping of
the heterogeneous population are among the assumptions in their study [25].
There are few available research on the COVID-19 vaccine distribution. Chen
et al. [8] explore the optimal COVID-19 vaccine allocation by applying an age-
structured simulation model. The results reveal that when DMs aim to minimise
deaths, the optimal approach is to prefer the old age group people over the
younger groups. Their research advises that when the goal is to reduce total
confirmed cases, the optimal strategy could be to consider the younger group first
in the vaccine allocation practice. Abbasi et al. [1] develop a DSS for optimising
the COVID-19 vaccine supply chain. They formulated a conceptual model that
considers a centralised booking system, risk profiling and prioritisation, and a
vaccine distribution system to propose an optimised vaccine allocation model.
2.3 Research gaps
Most of reviewed mathematical models only work for single period allocations
and they use static parameters (i.e., potential changes in parameters in a given
timeframe are not considered). Moreover, in-line with Lemmens et al. [18] find-
ings, very few studies have considered uncertainties (for instance, through sce-
nario analysis [22]) when developing models to address the vaccine distribution
challenges.
Besides, majority of mathematical models do not account for balancing mul-
tiple objective when investigating allocation alternatives. To the best of our
knowledge, available models have been rarely developed in close collaboration
with public health authorities. Lemmens et al. [18] suggest that the preferences
of different stakeholders have to be taken into account for obtaining a set of
economical, technological, and value key performance indicators that need to
be satisfied by the design. Mills and Salisbury [21] contend that without close
collaboration with practitioners models often lack relevance to and applicability
for practice. In summary, there is a need for COVI-19 vaccine allocation models
that realise the features of the in-country COVID-19 vaccine allocation problem
while accounting for stakeholders’ concerns and priorities.
3 Evidence-based mathematical model for COVID-19
vaccine allocation
3.1 Problem description
We describe the in-country COVID-19 vaccine distribution network as follows
based on our discussions with public health authorities in our interviews. The
vaccine distribution networks within countries often start from the main entry
points of the country (e.g., international airport(s)), in which COVID-19 vaccine
supplies would arrive in multiple supply waves. The first important decision is
to locate storage facilities to store entered vaccines. The next critical decision is
to allocate vaccines and transportation means to different facilities to distribute
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the vaccine in the network further. In different time steps, a distinct amount of
vaccines would be allocated to localised (municipalities or districts) facilities of
the country before final distribution (i.e., last mile delivery cf. Figure 2).
The distribution of a scarce amount of different types of COVID-19 vaccines
to each municipality for an effective immunisation program relies on the central
vaccine allocation problem (CVAP). The DMs must simultaneously consider a
variety of constraints in making the allocation decision, such as the type of the
vaccine, the size and distribution of the priority groups in the country, and the
current infection status. Moreover, multiple objectives must be considered in the
CVAP such as total coverage achieved at the national level and equity achieved
across the municipalities. The cost of logistics can also be a concern, although
less crucial, due to implications of decisions on saving human lives.
To simplify the problem and further investigation through mathematical
modelling, assumptions are inevitable. We made the following assumptions in
our methodology (derived from our discussion with authorities):
– The number and location of main entry points (MEPs), national storage
facilities (NSFs), and regional/municipality facilities (RMFs) are known.
– The demands for vaccines are assumed to be measured by doses for each
individual at targeted municipalities. The number of individuals and priority
groups are known. Vaccines, however, are allocated in batches,
– Required times for handling the vaccines (sorting and packaging) are as-
sumed to be negligible for the problem.
– It is assumed that the time horizon of the operation can be divided into mul-
tiple time steps. In each time step, once the allocation decision is made, the
vaccines will be immediately shipped to target facilities (i.e., time divergence
between deliveries at different facilities can be neglected at this stage).
– The CVAP does not consider the transportation of the vaccines within-
country since the 3PL company, which has enough logistics capacity, will
be responsible for the transportation.
– Since the local distribution of vaccines within each municipality differs, the
question regarding how the vaccines will be delivered in the last mile is
considered to be out of the scope of the problem.
3.2 Model description
Based on the insights from the background study (cf. Section 2) and interviews
with public health authorities [4], we identified multiple criteria for allocating
vaccines to each priority group in municipalities. The following three criteria
have been commonly highlighted in the literature and expressed by stakeholders
during the interview (as critical objectives).
– Efficacy is the performance dimension that shows the effectiveness of vaccine
allocation [26, 7, 9, 17, 3, 6, 16, 15, 1, 8] . Demand coverage achieved among
municipalities and priority groups are the main efficacy measures we consider
in this project.
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– Efficiency and sustainability are the dimensions related to the cost and envi-
ronmental friendliness of delivering a vaccine [18]. In this study, we consider
the cost of delivering the vaccine to each municipality, respectively. Logistics
costs between national storage and municipalities are used to calculate the
total cost of the model.
– Equity is the dimension that shows the vaccine allocation’s fairness degree
[21, 14, 23, 25]. For instance, distance to “perfect equity” is one of the per-
formance metrics for measuring equity, where perfect equity is defined in
terms of the priority-weighted proportional allocation amount.
To represent the problem in a mathematical form for further exploration,
we propose developing a mixed-integer linear model. The main features of the
model are explained as follows.
– Multiple vaccine types: vaccines may differ in terms of their batch sizes, the
number of doses required per person, amount of supply, cost of transporta-
tion.
– Multiple priority groups: in each demand location, there can be several
groups of the population to be vaccinated. The priority weights for each
priority group can be assigned. The DM can assign different weights to dif-
ferent priority groups and analyse solutions before making a final decision.
– Minimum coverage level: the DM can also set a minimum coverage threshold
for each priority group at each municipality. We apply a large infeasibility
penalty if it is not possible to achieve the minimum coverage levels.
– Sequential vaccination between multiple priority groups: the DM can choose
vaccinating different priority groups simultaneously or sequentially (i.e., after
completing a given percentage of a group with higher priority).
– Objective weights: the DM can give different weights for cost and equity
objectives, and obtain multiple solutions. From the model output, a Pareto
front is generated that presents the value of different solutions for different
objectives.
– Implementation of minimum coverage threshold for priority groups in mu-
nicipalities.
Our model determines the optimum amount of vaccines to be allocated to
regional and municipality facilities such that the total uncovered demands, lo-
gistics costs, transportation footprint, and the distance to perfect equity are
minimised. The objectives of the model have conflicting natures; improving the
coverage of demands and equity would primarily increase the logistics costs and
footprint, which is not desired. For the sake of brevity, we only describe the
proxies in informal terms in this section.
First objective – effectiveness: This objective minimises the total uncovered
vaccines demand, as formulated below. It consists of the summation of differences
between the sent vaccines to RMFs and their relevant quantity of demands in
different priority groups. Our model considers that multiple vaccines have to be
sent to RMFs while the minimum amount of demand coverage has to be decided
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by the DM(s).
Minimise uncovered vaccines demand =Total vaccines demand
– Total allocated and shipped vaccines
Second objective – efficiency: The minimisation of allocation costs consists of
ground transportation cost, air transportation cost, and penalty cost, as formu-
lated below. The ground and air transportation costs include the transit costs
from MEPs to NSFs, and from NSFs to RMFs through ground and air fleets. To
account for the impact of vaccine wastage, the model considers an extra cost for
each vaccine that is not allocated and transported to facilities in the network.
Minimise allocation cost =Ground transportation cost + Air transportation cost
+ Penalty cost for extra/shortcoming allocation
Third objective – sustainability: The minimisation of transportation foot-
print consists of considering footprint for transportation means given the travel
distance, the mode of transportation (ground vs. air), and the vaccine storage
requirement (cold chain equipment has fewer environmental impact than ultra
cold chain equipment).
Minimise transportation footprint =Ground transportation footprint
+ Air transportation footprint
+ Wastage footprint
Fourth objective – equity: The minimisation of allocation discrepancies is de-
fined as the distance to perfect proportion allocation amount. That is, given the
scarce supplies and the needs of municipalities, we find the amount that corre-
sponds to proportional allocation (what would each municipality get if supplies
are proportionally allocated) and tries to reduce the discrepancy between the
amount sent and the proportional allocation.
Minimise allocation discrepancies =
∑
(total shipped vaccines
− the proportional allocation) for all regions
4 Illustrative example
This section,illustrates our approach for generating alternatives to support the
COVID-19 vaccine allocation using two examples. In the first example, as shown
in Figure 3, we consider two municipalities and two priority groups in each
municipality, where priority group 1 is prioritised over priority group 2. We
assume that the vaccine supply is 300 units.
Decision support for COVID-19 vaccine allocation 9
Fig. 3. Example case illustration
Demands, priority coefficients, and the equity measures are as provided in
Table 1.
Table 1. Demand and priority coefficients for the example case I
Municipality Priority group Priority coefficient Demand Equity threshold
M1 P1 0.30 100 90
M1 P2 0.20 100 60
M2 P1 0.30 100 90
M2 P2 0.20 100 60
By running the optimisation model, we calculated allocated vaccine amounts,
the coverage of each group in each municipality, and the difference between
the number of allocated vaccines and perfect equity levels were as presented in
Table 2. As the table depicts, the average percentage coverage would be 75%
overall, and 85% for P1 and 65% for P2.
Table 2. Sent vaccine amounts, coverages, and deviation from the equity threshold for
the example case
Municipality Priority group Allocated vaccine Coverage% Deviation from the equity %
M1 P1 100 100 10
M1 P2 80 80 20
M2 P1 70 70 -20
M2 P2 50 50 -10
In the second example, we considered a network with four municipalities
(M1-M4) that have vaccine demands of 60, 30, 40, and 70 units, respectively.
M1-2 are closer to the main entry point than M3-4. We also assumed the vaccine
supply as 100 units. This example represents a more realistic setting as (i) the
available quantity of supply is much smaller than the demand for vaccines (ii)
different municipalities often have different travel time to the main entry point.
Our analysis for the second example reveals that tradeoffs between equity
and efficiency objectives are huge. Figure 4 illustrates coverage graph when more
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importance weight has been assigned to logistics costs. Since sending vaccines
to M1 and M2 is respectively less costly, the model allocates as much vaccine
as possible to these two municipalities consecutively, considering the minimum
threshold constraint.
Fig. 4. Changes in demand coverage by assigning higher importance weight to logistics
costs (blue: current coverage; orange: distance to equity threshold)
However, when more importance weight is given to the equity criterion, the
allocation results change considerably, as shown in Figure 5.
Fig. 5. Changes in demand coverage by assigning higher importance weight to equity
(blue: current coverage; orange: distance to equity threshold)
To illustrate tradeoffs further, we provide a Pareto frontier diagram for logis-
tics costs vs. the average absolute value of percentage deviation from the perfect
equity level among municipalities (see Figure 6). Blue dots on this diagram refer
to each alternative allocation policy.
5 Conclusions and perspectives
Over the course of year 2020, public health authorities in many countries faced
a task of unprecedented scale: to ensure effective and efficient vaccine delivery
to frontline healthcare workers, at-risk groups, and eventually all people while
accounting for sustainability and equity. In this article, we argue that equitable
allocation of scarce COVID-19 vaccines is still a challenging task.
Our primary analysis revealed that planning for an over-average equitable
vaccine allocation could mean accepting nearly 40% more logistics costs. While
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Fig. 6. Tradeoffs between efficiency and equity objectives
in high-income countries, accepting high logistics costs may not be an issue to
public health authorities, this would be challenging in LMICs. Despite the sig-
nificance of the challenge, the literature lacks effective decision support systems
to help public health authorities. Particularly, in the presence of multiple objec-
tives, illustrating tradeoffs between conflicting criteria is a need that has often
been neglected in the literature.Previous studies in vaccine allocation and dis-
tribution [26, 7, 9, 17, 3, 6, 16, 15, 1, 8] ignore the sustainable aspect of the
pandemic vaccine supply chain. Only one study by Huang et al. [16] considers
the types of the vaccine in vaccine allocation decision. Based on this, we have
presented the first characteristics of a decisions support system able to serve as
a basis to support public health authorities for current and future pandemics.
The main assumptions of this research have been derived and validated in close
collaboration with authorities involved in the COVID-19 response.
To sum up, this works is still in its infancy, and there can be numerous av-
enues for research. First, the proposed model should be tested and validated
with several real cases. Differences between contexts could imply that a gen-
eralised approach to the allocation problem across multiple countries/contexts
would be difficult. One solution is to allow enough flexibility for model features
(constraints, variables and parameters) so that they could to be adapted. Sec-
ond, we acknowledge that since there are different infrastructure capabilities in
distinct countries, the cost picture can differ from country to country and sup-
ply chains for delivering various COVID-19 vaccines within regions may differ
hugely. Moreover, vaccines delivery to main entry points would naturally trig-
ger an increase in the demand for transportation means with specific coldchain
requirements. One expected result is the raised transportation costs, which will
also add to the logistics costs formulated in our model. Third, other metrics
for equity have to be investigated. Other metrics which could be considered to
assess equity are the percentage of residents age 55 and older; the percentage
of minority residents; the percentage of residents who live below the poverty
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line; the region’s prevalence of diabetes and hypertension; the region’s two-week
COVID-19 infection rate; and the percentage of residents who are unvaccinated.
Fourth, this was only the first step for our DSS development. Following the
process outlined in Figure 1 we need to run a sensitivity analysis on the decision
alternatives that have been generated by our model. Given the uncertainties in
the context of COVID-19 pandemic response, some information might be missing
such as the number of available vaccines. Thus, DMs could be interested to check
the sensitivity of decision alternatives (second component) based on different
scenarios. Such analysis will be conducted through a pool of scenarios developed
by reviewing literature and using the help of experts. Thereafter, alternatives
can be ordered based on the performance in the sensitivity analysis step. Such
information can provide a basis to present the outcomes in a meaningful way to
DMs through an online dashboard. We intend to verify the model with public
health authorities and collect their information needs to develop an intuitive web-
based platform. We intend to offer a set of DMs from different high-, middle-,
and low-income countries to test and validate the platform in the final stages of
our research project.
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